Preferred Label : Rilimogene Galvacirepvec/Rilimogene Glafolivec;
NCIt synonyms : PROSTVAC-VF-TRICOM; PROSTVAC-VF/TRICOM; Recombinant Vaccinia-Fowlpox-Prostate-specific Antigen-TRICOM Vaccine; PROSTVAC-V-PROSTVAC-F; Rilimogene Galvacirepvec-Rilimogene Glafolivec; Recombinant Vaccinia-B7.1 Vaccine; PROSTVAC-V/F; Recombinant Vaccinia-B7.1;
NCIt definition : A vaccine formulation consisting of rilimogene galvacirepvec (V-PSA-TRICOM; PROSTVAC-V),
a recombinant vaccinia virus, and rilimogene glafolivec (F-PSA-TRICOM; PROSTVAC-F),
a recombinant fowlpox virus, with potential immunostimulating and antineoplastic activities.
Both viruses encode modified forms of human prostate specific antigen (PSA) and the
three co-stimulatory molecule transgenes (TRIad of COstimulatory Molecules; TRICOM),
B7.1 (CD80), intercellular adhesion molecule-1 (ICAM-1), and lymphocyte function-associated
antigen-3 (LFA-3). Using a prime-boost vaccine regimen, with a primary vaccination
of rilimogene galvacirepvec followed by multiple booster vaccinations of rilimogene
glafolivec, the PSA-TRICOM vaccines infect antigen-presenting cells (APCs), such as
dendritic cells (DCs). Upon processing and expression of the PSA and TRICOM proteins
on their surfaces, the DCs are able to initiate cytotoxic T-lymphocyte (CTL) responses
against PSA-expressing cancer cells. The combination of PSA and TRICOM greatly enhances
T-cell activation and T-cell-mediated tumor cell killing.;
Drug name : PROSTVAC;
NCI Metathesaurus CUI : CL520248;
Origin ID : C132990;
UMLS CUI : C4321471;
Semantic type(s)
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
